CU20200029A7 - PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES OF VIRAL ORIGIN - Google Patents

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES OF VIRAL ORIGIN

Info

Publication number
CU20200029A7
CU20200029A7 CU2020000029A CU20200029A CU20200029A7 CU 20200029 A7 CU20200029 A7 CU 20200029A7 CU 2020000029 A CU2020000029 A CU 2020000029A CU 20200029 A CU20200029 A CU 20200029A CU 20200029 A7 CU20200029 A7 CU 20200029A7
Authority
CU
Cuba
Prior art keywords
ifn
treatment
pharmaceutical composition
respiratory diseases
type
Prior art date
Application number
CU2020000029A
Other languages
Spanish (es)
Inventor
Rivero Iraldo Bello
Legrá Iván Campa
Roberts Yaquelin Duncan
Nieto Gerardo Enrique Guillén
Suárez Claudia Martínez
BLOMQUIST Dania Marcia VÁZQUEZ
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Priority to CU2020000029A priority Critical patent/CU20200029A7/en
Priority to PCT/CU2021/050003 priority patent/WO2021233484A1/en
Publication of CU20200029A7 publication Critical patent/CU20200029A7/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>Composición farmacéutica para el tratamiento de enfermedades respiratorias agudas de origen viral que comprende interferón (IFN) tipo I e IFN gamma donde la cantidad de IFN tipo I (UI) es entre 5 y 13 veces superior a la cantidad de IFN gamma (UI). Composición farmacéutica para el tratamiento de pacientes con persistencia de un virus que causa enfermedades respiratorias agudas que comprende IFN tipo I e IFN gamma donde la cantidad de IFN tipo I (UI) es entre 5 y 13 veces superior a la cantidad de IFN gamma (UI). La invención adicionalmente contempla la combinación de IFN tipo I (UI) y IFN gamma (UI) con otros antivirales.</p><p>Pharmaceutical composition for the treatment of acute respiratory diseases of viral origin comprising interferon (IFN) type I and IFN gamma where the amount of IFN type I (UI) is between 5 and 13 times higher than the amount of IFN gamma ( IU). Pharmaceutical composition for the treatment of patients with persistence of a virus that causes acute respiratory diseases comprising IFN type I and IFN gamma where the amount of IFN type I (IU) is between 5 and 13 times higher than the amount of IFN gamma (IU ). The invention additionally contemplates the combination of IFN type I (UI) and IFN gamma (UI) with other antivirals.</p>

CU2020000029A 2020-05-20 2020-05-20 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES OF VIRAL ORIGIN CU20200029A7 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CU2020000029A CU20200029A7 (en) 2020-05-20 2020-05-20 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES OF VIRAL ORIGIN
PCT/CU2021/050003 WO2021233484A1 (en) 2020-05-20 2021-05-19 Pharmaceutical composition for the treatment of respiratory diseases of viral origin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000029A CU20200029A7 (en) 2020-05-20 2020-05-20 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES OF VIRAL ORIGIN

Publications (1)

Publication Number Publication Date
CU20200029A7 true CU20200029A7 (en) 2022-01-13

Family

ID=77338445

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000029A CU20200029A7 (en) 2020-05-20 2020-05-20 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES OF VIRAL ORIGIN

Country Status (2)

Country Link
CU (1) CU20200029A7 (en)
WO (1) WO2021233484A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23432B6 (en) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech STABILIZED FORMULATIONS CONTAINING GAMMA AND ALFA INTERFERONS IN POTENTIAL PROPORTIONS

Also Published As

Publication number Publication date
WO2021233484A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
CO2022011728A2 (en) Compositions and uses of glp-1
CL2022001743A1 (en) Gamma-Hydroxybutyrate (GHB) Dosage
MX2022016405A (en) 1&#39;-cyano nucleoside analogs and uses thereof.
ES2186660T3 (en) COMBINATION THERAPY TO ERADICATE HCV-RNA DETECTABLE IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION.
PH12020550051B1 (en) Glp-1 compositions and uses thereof
CL2022002481A1 (en) Antiviral compounds and methods for administration thereof
MX369259B (en) ORAL DOSAGE OF PEPTIDE COMPOUNDS SIMILAR TO GLAUCON-1 (GLP-1).
PH12020551709A1 (en) Antiviral immunotropic agent for the treatment of acute respiratory viral infections
CO2021014024A2 (en) Methods for treating muscular dystrophy with casimersin
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
BR112015018259A2 (en) REDUCED PRO-INFLAMMATORY RESPONSE
MX2021003599A (en) Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation.
PE20210116A1 (en) ORAL ADMINISTRATION OF GLP-1 PEPTIDE ANALOGS
CU20200029A7 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES OF VIRAL ORIGIN
CO2020001322A2 (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
CO2021002721A2 (en) Liquid paracetamol suspensions
BR112022019679A2 (en) COMPOSITION
BR112023019795A2 (en) NASAL COMPOSITIONS COMPRISING ALCAFTADINE
CL2022000990A1 (en) Combination of a cxcr7 antagonist with a s1p1 receptor modulator
AU2018324427A1 (en) Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics
AR080541A1 (en) TREATMENT FOR ENDOMETRIOSIS
Kannan et al. Coagulopathy in dengue fever patients
BR112021019979A2 (en) Treatment involving interleukin-2 (il2) and interferon (ifn)
CL2024000431A1 (en) Against inflammatory bowel diseases involving disruption of ccr9:drd5 heteromer assembly
BR112023026272A2 (en) COMBINATION, PHARMACEUTICAL COMPOSITION, AND PARTS KIT